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Abstract: Deoxynojirimycin (DNJ) is the archetypal iminosugar, in which the configuration of the
hydroxyl groups in the piperidine ring truly mimic those ofd-glucopyranose; DNJ and derivatives have
beneficial effects as therapeutic agents, such as anti-diabetic and antiviral agents, and pharmacological
chaperones for genetic disorders, because they have been shown to inhibit α-glucosidases from
various sources. However, attempts to design a better molecule based solely on structural similarity
cannot produce selectivity between α-glucosidases that are localized in multiple organs and tissues,
because the differences of each sugar-recognition site are very subtle. In this study, we provide the
first example of a design strategy for selective lysosomal acid α-glucosidase (GAA) inhibitors focusing
on the alkyl chain storage site. Our design of α-1-C-heptyl-1,4-dideoxy-1,4-imino-l-arabinitol (LAB)
produced a potent inhibitor of the GAA, with an IC50 value of 0.44 µM. It displayed a remarkable
selectivity toward GAA (selectivity index value of 168.2). A molecular dynamic simulation study
revealed that the ligand-binding conformation stability gradually improved with increasing length of
the α-1-C-alkyl chain. It is noteworthy that α-1-C-heptyl-LAB formed clearly different interactions
from DNJ and had favored hydrophobic interactions with Trp481, Phe525, and Met519 at the alkyl
chain storage pocket of GAA. Moreover, a molecular docking study revealed that endoplasmic
reticulum (ER) α-glucosidase II does not have enough space to accommodate these alkyl chains.
Therefore, the design strategy focusing on the shape and acceptability of long alkyl chain at each
α-glucosidase may lead to the creation of more selective and practically useful inhibitors.
Keywords: iminosugars; glucosidase inhibitor; lysosomal acid α-glucosidase; ER α-glucosidase II;
ligand docking; molecular dynamics; drug design
1. Introduction
Glycosidases are involved in a wide range of important biological processes; these include
carbohydrate catabolism in the intestines, lysosomal catabolism of glycolipids, biosynthesis of
oligosaccharide chains, and quality control of N-linked glycoproteins in the endoplasmic reticulum (ER).
Molecules 2020, 25, 2843; doi:10.3390/molecules25122843 www.mdpi.com/journal/molecules
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Accordingly, the inhibition of these glycosidases can have profound effects on the intestinal digestion,
catabolism of glycolipids in lysosome, the maturation, transport, and secretion of glycoproteins,
and can alter cell-cell or cell-virus recognition processes. This provides a basis for the potential use of
glycosidase inhibitors in diabetes, genetic lysosomal disorders, cancer, and viral infection [1–3].
Iminosugars are sugar mimics with a nitrogen atom in place of the ring oxygen of monosaccharides.
They usually bind to the active sites of glycosidases in a reversible and competitive manner, as a result
of their structural resemblance to the terminal sugar moiety in the natural substrates. A large number
of iminosugars have been discovered from natural sources. They are classified into five structural
classes: polyhydroxylated pyrrolidines, piperidines, indolizidines, pyrrolizidines and nor-tropanes [4,5].
Among them, the inhibition specificity of piperidine iminosugars (Figure 1) is usually easy to predict
from the configurations of hydroxy groups, which are identical to those of the corresponding pyranose.
For example, 1,5-dideoxy-1,5-imino-d-glucitol (deoxynojirimycin (DNJ)) corresponding to glucose
in the pyranose configuration has high inhibition specificity against α-glucosidases. Similarly the
polyhydroxylated piperidine analogues of mannose and galactose, 1,5-dideoxy-1,5-imino-d-mannitol
(deoxymannojirimycin (DMJ)), and 1,5-dideoxy-1,5-imino-d-galactitol (deoxygalactonojirimycin (DGJ)),
show the expected inhibition of α-mannosidase and α-galactosidase, respectively [6]. The structural
basis of the inhibition of glycosidases by these compounds is clear, but this inhibition selectivity
based on high similarity with the substrate may cause side effects. The anti-diabetes drug, miglitol,
was designed from DNJ to suppress postprandial hyperglycemia, by inhibiting the hydrolysis of
disaccharides such as maltose, isomaltase, and sucrose in the brush border membrane, and delaying
the absorption of carbohydrates from the small intestine. However, miglitol is nearly completely
absorbed from the intestinal tract [7]. Therefore, it inhibited not only intestinal α-glycosidases, but
also the processing ER enzymes α-glucosidase I and II [8]. Therefore, closely mimicking iminosugars
can be expected to give potent inhibition, but may cause selectivity problems between glycosidase
isozyme species.
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This study is focused on lysosomal acid α-glucosidase (GAA; EC 3.2.1.20). GAA is a retaining 
exo-glucosidase responsible for the cleavage of the α-glycosidic bond of glycogen to release glucose. 
Pompe disease is caused by mutations in the gene that encodes the GAA; these mutations result in 
reduced cellular enzyme activity, and the progressive accumulation of glycogen in the lysosomes of 
heart, skeletal muscles, and other tissues [9]. At present, more than 300 different point mutations 
have been identified within the GAA gene [10]. These GAA mutations result in a decrease of enzyme 
stability, and a subsequent decrease in the amount of enzyme activity in lysosome. Pharmacological 
chaperones, such as some reversible competitive inhibitors, appear to be able to act as a template 
that stabilizes the native folding state in the ER by occupying the active site of the mutant enzyme, 
thus allowing its maturation and trafficking to the lysosome [11,12]. It was reported that DNJ can act 
as a pharmacological chaperone, while also showing inhibition of ER α-glucosidase I and II, which 
might be linked to its side effects [13,14]. 
Thus, our strategy has been to design effective pharmacological chaperones for Pompe disease 
that affect the stability of GAA, which not only show a strong affinity for GAA, but also do not 
interfere with glycoprotein processing. We herein describe that the glucosidase inhibitor 
1,4-dideoxy-1,4-imino-L-arabinitol (LAB) with α-1-C-heptyl chain is a more selective inhibitor of 
GAA than DNJ. We also investigated the effect of α-1-C-alkyl chain length on the selectivity for GAA 
vs. ER α-glucosidase II. An additional aim was to demonstrate the molecular docking properties of 
α-1-C-alkyl-LAB with GAA. 
2. Results and Discussion 
2.1. Structural Similarity of Active Site between GAA and ER α-Glucosidase II 
To date, various DNJ derivatives and stereoisomers have been synthesized and investigated for 
the inhibition activities toward GAA [15,16], and ER α-glucosidase II [17]; however, there are no 
reports of the selective inhibition of each enzyme.  
Several crystal structures of human GAA and mouse ER α-glucosidase II have been deposited 
in the Protein Data Bank. Among them, we selected the complex crystal structure of GAA with DNJ 
(PDB ID: 5NN5) and the complex crystal structure of ER α-glucosidase II with DNJ (PDB ID: 5IEE); 
these structures were superimposed on each other by using the Protein Structure Alignment tool in 
Maestro. Our selected complex crystal structures used DNJ as a common ligand, suitable for 
clarifying the different interactions between both enzymes. The amino acids around 5Å of DNJ are 
shown in Figure 2. The orientation and the conformation of DNJ are almost completely overlapped 
between GAA (light green) and ER α-glucosidase II (yellow). Moreover, as shown in Figure 2, amino 
acid residues surrounding the DNJ bound to the sugar recognition site of both enzymes are almost 
identical; the only two differences are that (i) Leu405 (GAA) has been replaced by Ile452 (ER 
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This study is focused on lysosomal acid α-glucosidase (GAA; EC 3.2.1.20). GAA is a retaining
exo-glucosidase responsible for the cleavage of the α-glycosidic bond of glycogen to release glucose.
Pompe disease is caused by mutations in the gene that encodes the GAA; these mutations result in
reduced cellular enzyme activity, and the progressive accumulation of glycogen in the lysosomes of
heart, skeletal muscles, and other tissues [9]. At present, ore than 300 different point mutations
have been identified within the GAA gene [10]. These GAA utations result in a decrease of enzyme
stability, and a subsequent decrease in the amount of enzyme activity in lysosome. Pharmacological
chaperones, such as some reversible competitive inhibitors, appear to be able to act as a te plate that
stabilizes the native folding state in the ER by occupying the active site of the mutant enzyme, thus
allowing its maturation and trafficking to the lysosome [11,12]. It was reported that DNJ can act as a
pharmacological chaperone, while also showing inhibition of ER α-glucosidase I and II, which might
be linked to its side effects [13,14].
Thus, our strategy has been to design effective pharmacological chaperones for Pompe disease
that affect the stability of GAA, which not only show a strong affinity for GAA, but also do
not interfere with glycoprotein processing. We herein describe that the glucosidase inhibitor
1,4-dideoxy-1,4-imino-l-arabinitol (LAB) with α-1-C-heptyl chain is a more selective inhibitor of
GAA than DNJ. We also investigated the effect of α-1-C-alkyl chain length on the selectivity for GAA
vs. ER α-glucosidase II. An additional aim was to demonstrate the molecular docking properties of
α-1-C-alkyl-LAB with GAA.
2. Results and Discussion
2.1. Structural Similarity of Active Site between GAA and ER α-Glucosidase II
To date, various DNJ deri atives and stereoisomers have been synthesized and investigated for
the inhibition activities toward GAA [15,16], and ER α-glucosidase II [17]; however, there are no reports
of the selective inhibition of each enzyme.
Several crystal structures of human GAA and mouse ER α-glucosidase II have been deposited
in the Protein Data Bank. Among them, we selected the complex crystal structure of GAA with DNJ
(PDB ID: 5NN5) and the complex crystal structure of ER α-glucosidase II with DNJ (PDB ID: 5IEE);
these structures were superimposed on each other by using the Protein Structure Alignment tool in
Maestro. Our selected complex crystal structures used DNJ as a common ligand, suitable for clarifying
the different interactions between both enzymes. The amino acids around 5Å of DNJ are shown in
Figure 2. The orientation and the conformation of DNJ are almost completely overlapped between
GAA (light green) and ER α-glucosidase II (yellow). Moreover, as shown in Figure 2, amino acid
residues surrounding the DNJ bound to the sugar recognition site of both enzymes are almost identical;
the only two differences are that (i) Leu405 (GAA) has been replaced by Ile452 (ER α-glucosidase II)
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and (ii) Ser676 (GAA) has been replaced by His700 (ER α-glucosidase II). Furthermore, the hydrogen
bonding, ionic and cation-pi network between these enzymes and DNJ were very similar (see Supporting
Information S1). These results suggested that the lack of specificity of DNJ may be attributed to the high
degree of structural and sequence similarity of glucose recognition site of GAA with ER α-glucosidases.
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2.2. Influence of α-1-C-alkylation of LAB on Inhibition of GAA and ER α-Glucosidase II
On the basis of these findings, we turned our attention to the design of selective GAA inhibitors,
with the goal of increasing the stability of GAA. Table 1 shows the 50% inhibitory concentrations
(IC50) of LAB and its α-1-C-alkyl derivatives against GAA and ER α-glucosidase II. DNJ was used as a
positive control. The parent compound, LAB, showed potent inhibitory activities against GAA and
ER α-glucosidase II, with an IC50 value of 0.52 and 2.8 µM respectively. Inhibition potency of GAA
was 3.5 times weaker than DNJ, whereas LAB was 2.9 times stronger inhibitor than GAA toward ER
α-glucosidase II. Consequently, selectivity for GAA against ER α-glucosidase II of LAB was 10 times
lower than DNJ. We next focused on the anomeric position and whether extending the alkyl chain at
this position might cause differential inhibition by LAB. Figure 3 shows the logarithm of the reciprocal
of pIC50 for α-1-C-alkyl-LAB against both enzymes as a bar graph. Of these compounds, with the
introduction of a propyl instead of a methyl group, the inhibitory activity toward both enzymes tends to
decrease, due to alkyl chain extension. Thereafter, both inhibitory activities were gradually recovered
going from propyl to heptyl due to the elongation of the alkyl chain. However, it is notable that there
is a large difference in the degree of reduction and recovery of the inhibitory activity for both enzymes.
The effect of inhibition of GAA was small; even the most reduced α-1-C-ethyl-LAB was only 21-fold
lower than LAB (Table 1). Furthermore, the inhibition of GAA was restored to the same level as LAB
in α-1-C-heptyl-LAB. In contrast, the influence on ER glucosidase inhibition is large. α-1-C-Ethyl-LAB
showed 193-fold weaker inhibition than LAB, and the inhibitory activity was not fully restored even
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when the alkyl chain was extended to heptyl. Consequently, α-1-C-heptyl-LAB displayed a remarkable
selectivity index (SI) of 168.2, which is 31-fold better relative to the parent LAB (Table 1).
Table 1. IC50 values (µM) for α-1-C-alkyl-LAB and related compounds against processing ER
α-glucosidase II (ER α-Glaase II) and lysosomal acid α-glucosidase (GAA).
IC50 (µM) Selectivity Index
n = Compounds ER α-Glcase II GAA ER α-Glcase II/GAA
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2.3. Analysis of GAA- Ligand Stable Binding Pose by Using MD Calculation
MD simulation can elucidate the dynamic changes in the interaction between target enzyme and
the ligands. Maintaining a stable str cture i t active site is an import nt factor for strong recognition
by the enzyme. To understand the structural basis of the interaction of α-1-C-alkyl-LAB with GAA,
we first studied the protein-ligand docking analyses of α-1-C-alkyl-LAB by using three GAA crystal
structures (PDB ID: 5NN5, 5NN6, and 5NN8), which have reported as the complex structures of GAA
with DNJ, miglitol, and acarbose, respectiv ly. They commonly contain several water molecules in
the ligand-binding site. Therefore, we c nsidered these water molecules in the docking analyses.
The docking analyses were performed using the grids generated from the crystal structures with two
t four w ter molecule combinations in 5NN5 and 5NN6 and the crystal structure with two water
molecules in 5NN8 (see Supp ting I for atio S2). By including water molecules in the docking
analyses, the docking poses of the co-crystalized ligands could be correctly reproduced. The best
docking score poses were selected from many poses generated using each grid and energy-minimized
to select one complex structure with the best binding interaction energy. Molecular dynamic (MD)
simulations were carried out using the docking structure as initial structures. In the result of the
MD simulation, the root mean square deviation (RMSD) of the protein heavy-atoms, compared
with the initial structure, initially increased, and then became almost stable. The 50 ligand binding
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conformations, sampled equally in time intervals from the trajectories between 24 ns and 48 ns, were
presented in Figure 4. Furthermore, Figure 5 shows the relationship between the extension of the
α-1-C-alkyl chain length and the variation of the ligand binding pose by using the RMSD as the
evaluation standard. We evaluated the variation of ligand binding pose from the viewpoint of the whole
ligand (light orange) and the pyrrolidine ring part (orange). Among these compounds, the parent LAB
and α-1-C-methyl-LAB remained the stable ligand-binding conformations, and their average RMSD
values were both less than 1.5Å in the ligand-binding site (Figure 4A,B and Figure 5). In contrast,
the introduction of short (ethyl and propyl) groups reduced the ligand-binding conformation stability
and the positions of the pyrrolidine ring and the overall orientations moved drastically (Figure 4C,D).
They resulted in the high variation of the position and the orientation of both the whole ligand and
the pyrrolidine ring moiety (Figure 5). Furthermore, we found that the ligand-binding conformation
stability gradually improved with increasing length of the alkyl chain; a much longer alkyl chain than
butyl is required for achieving them (Figure 4E–H). Therefore, the introduction of longer (hexyl and
heptyl) groups reduced the fluctuations of the ligand-binding conformation, and it was observed that
the positions of the pyrrolidine ring were very stable (Figure 4G,H).
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2.4. Hydrogen Bonding Interactions and Cation-pi Interactions between GAA and DNJ, LAB,
and α-1-C-heptyl-LAB
In order to investigate the interaction between GAA and the ligands, we modelled the
three-dimensional structures of the complex structures by GAA with LAB and α-1-C-heptyl-LAB,
using the docking protocol. As shown in Figure 6B, the positively charged nitrogen and the hydroxyl
groups of LAB formed hydrogen bonds with Asp404, Asp518, Arg600, and Asp616. Furthermore,
the pyrrolidine ring part of LAB had the favorable cation-pi interaction with Trp376 and Trp516 and
ionic interaction with Asp404, Asp443, Asp518, and Asp616. The schematic diagram of hydrogen
bonding interactions and cation-pi interactions between GAA and LAB was similar to that of DNJ
(Figure 6A), except for the cation-pi interaction with Phe649 and ionic interaction with His674 of DNJ.
In contrast, α-1-C-heptyl-LAB formed clearly different interactions with GAA (Figure 6C). It formed
the additional cation-pi interaction and hydrogen bonds with Trp481, whereas it lacked hydrogen
bonds with Asp616 and Arg600 and ionic interaction with Asp616. Furthermore, it is notable that the
heptyl group of α-1-C-heptyl-LAB formed hydrophobic interaction with Trp481, Phe525, and Met519
of the alkyl chain storage pocket of GAA. Figure 6D showed the 25 binding poses of LAB (blue)
and α-1-C-heptyl-LAB (green) obtained from the MD simulations. Both compounds reduced the
fluctuations of the ligand-binding conformation, and the positions of the pyrrolidine ring were very
stable. Therefore, the number of hydrogen bonds formed by α-1-C-heptyl-LAB is smaller than that of
DNJ and LAB, but it was thought to be strongly affected by hydrophobic interactions.
2.5. Comparison of GAA and ER α-Glucosidase II Focusing on LAB-alkyl Chain Storage Pocket
On the basis of these findings, we hypothesized that the difference in the storage sites of the alkyl
chains would also affect the selectivity of GAA and ER α-glucosidase II. Based on this hypothesis, we
first identified each storage site (Figure 7). At first, the crystal structures of GAA (PDB ID: 5NN5) and
ER α-glucosidase II (PDB ID: 5IEE) were superposed using the Protein Structure Alignment tool in
Maestro. Subsequently, the complex structure of each enzyme with α-1-C-hexyl-LAB was extracted
from the MD simulation and superimposed on them (Figure 7). Figure 7A showed the amino acids
of GAA and ER α-glucosidase II within 5Å surrounding the α-1-C-hexyl-LAB. The amino acids that
differ between GAA (magenta) and ER α-glucosidase II (blue) were displayed in the square box. As
shown in Figure 2, the amino acid residues surrounding the sugar recognition site of both enzymes
were almost common. In sharp contrast, it was revealed that the amino acid residues surrounding
the α-1-C-hexyl-LAB binding part in each active site was clearly different. We focused especially on
three amino acids: Ala284, Leu650, and Ser676 (red solid square box), which composed the LAB-alkyl
chain storage pocket. In case of ER α-glucosidase II, these amino acids were replaced by Phe307,
Phe674, and His700. As shown in Figure 7B,C, the substitution of these three amino acids causes a
large difference in the opening part (red dotted circle) of each active site. Similarly, from the view of
the outside of the opening, it can be seen that GAA has a wider opening than ER α-glucosidase II
(Figure 7E,F). Figure 7D showed the superimposition of both protein surface. Consequently, the space
of the alkyl chain storage pocket in ER α-glucosidase II was narrower than GAA, and it cannot
accommodate the extension of alkyl chains.
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Figure 7. Difference of - l l chain storage pocket in GAA and ER α-glucosidase II. (A) The amino
acids of GAA and ER α-glucosidase II within 5Å surrounding the α-1-C-hexyl-LAB. The amino acids
that differ between GAA (magenta) and ER α-glucosidase II (blue) were displayed in the square
box. (B) The protein surface of GAA and the characteristic three amino acids, which composed the
opening part (red dotted circle) of the active site. (C) The protein surface of ER α-glucosidase II and the
characteristic three amino acids which composed the opening part (red dotted circle) of the active site.
(D) The superimposition of each protein surface of GAA and ER α-glucosidase II. Docking pose of
α-1-C-hexyl-LAB against GAA was superimposed with them. (E) GAA protein surface from the view
of the outside of the opening part of the active site. (F) ER α-glucosidase II protein surface from the
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2.6. GAA Stabilization Effect of LAB, α-1-C-ethyl-LAB and α-1-C-heptyl-LAB
With respect to LAB and α-1-C-heptyl-LAB having a different binding pocket in the
sugar-recognition site toward GAA, we next investigated the effect of these compounds on the
stabilization of this enzyme at 47 ◦C (Figure 8). GAA was incubated in 100 mM McIlvaine buffer
(pH 6.8) containing 0.25% sodium taurocholate and 0.1% Triton X-100 for 0, 20, 40, and 60 min,
and the remaining enzyme activity was determined with 4-methylumbelliferl-α-d-glucopyranoside as
substrate. The enzyme activity was 83% lost within 60 min under incubation without test samples,
while the incubation with α-1-C-heptyl-LAB effectively stabilized GAA. The enzyme activity remained
over 94% even under the incubation for 60 min in the presence of 10 µM α-1-C-heptyl-LAB (Figure 8).
This behavior is similar to that of 10 µM LAB, but the stabilization effect was slightly weaker than
LAB (89% activity remained at 60 min). Therefore, it is considered that α-1-C-heptyl-LAB forms an
appropriate hydrogen ion network in the sugar-recognition site, which is different from LAB and DNJ,
and stabilizes GAA. In contrast, 10 µM α-1-C-ethyl-LAB could not sufficiently protect the enzyme
activity (50% activity remained at 60 min). These results correlate with stability in the MD analysis.
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Figure 8. Effect of LAB, α-1-C-ethyl-LAB, and α-1-C-heptyl-LAB on the in vitro thermostability.
GAA was incubated at 47 ◦C in 100 mM sodium citrat buffer (pH 6.8) containing 1 g/mL of bovine
serum albumin (BSA) at various incubation times with or without imin sugars. Each value represents
the mean ± SEM (n = 3 .
3. Experimental Section
3.1. Chemistry
1,4-Dideoxy-1,4-imino-l-arabinitol (LAB) was prepared from l-arabinose, by an identical method to
that used for the synthesis of 1,4-dideoxy-1,4-imino-d-arabinitol (DAB) [18–21]. α-1-C-Alkyl-LAB with
various lengths of side chains from C1 to C7 at the 1-position were synthesized, as previously described [8].
3.2. Enzyme Inhibition Assays
The inhibitory activity toward lysosomal acid α-glucosidase (GAA) was measured with Myozyme
(Genzyme; Boston, M , USA) as the enzyme source, and 4-methylumbelliferyl-α-d-glucopyranoside
(Sigma-Aldrich Co.; St. Louis, Mo, USA) as substrate. The reaction mixture consisted 100 mM McIlvaine
buffer (pH 6.8), 0.25% sodium taurocholate and 0.1% Triton X-100 (Nacalai Tesque Inc.; Kyoto, Japan),
and the appropriate amount of enzyme. The reaction mixture was pre-incubated at 0 ◦C for 45 min,
and the reaction was started by the using 4 mM substrate solution, followed by incubation at 37 ◦C for
30 min. The reaction was stopped by the addition of 1.6 mL of the solution of 400 mM Glycine-NaOH
solution (pH 10.6). The released 4-methylumbelliferone was measured (excitation 362 nm, emission
450 nm) with a F-4500 fluorescence spectrophotometer (Hitachi, Tokyo, Japan). ER α-glucosidase II
was prepared from the rat liver according to the method of Hino et al. [22]. For ER α-glucosidase II
activities, 4-nitrophenyl-α-d-glucopyranoside (Sigma-Aldrich Co.; St. Louis, MO, USA) was used
as substrate. The reaction mixture contained phosphate buffer (pH 6.8), 0.25% sodium taurocholate,
and the appropriate amount of enzyme. The reaction mixture was pre-incubated at 0 ◦C for 30 min,
and the reaction was started by the using 4 mM substrate solution, followed by incubation at 37 ◦C for
30 min. The reaction was stopped by adding 0.4 mL of 400 mM Na2CO3. The released p-nitrophenol
was measured spectrometrically at 400 nm.
3.3. MD Calculations
The crystal structures of GAA with deoxynojirimycin, miglitol, and acarbose (PDB ID: 5NN5, 5NN6
and 5NN8) were downloaded from the Protein Data Bank. The preparations of the protein structures
were performed using Maestro Protein Preparation Wizard (Schrödinger, LLC, New York, NY, USA). After
removing water molecules other than those used in docking analysis, hydrogen atoms were added at pH
6.8. The docking analyses were performed with the standard precision (SP) mode of Glide (version 7.9,
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Schrödinger, LLC, New York, NY, USA) using the grids generated from the crystal structures with two to
four water molecule combinations in 5NN5 and 5NN6 and the crystal structure with two water molecules
in 5NN8. The best docking score poses were selected for each grid and energy-minimized to select one
complex structure with the best binding interaction energy. These docking structures were solvated in a
cubic simulation box using a simple point charge (SPC) water model with periodic boundary conditions.
The net charge of the system was neutralized by addition of sodium and chloride ions. MD simulations
were performed in 48 ns at 310 K and 1 bar and NPT ensemble using Desmond (version 5.4, Schrödinger,
LLC, New York, NY, USA) [23,24]. Electrostatic interactions were calculated using the Particle Mesh Ewald
with a cut-off distance of 9.0Å. MD simulations were performed using the OPLS3 force field. All calculations
were performed using the Schrödinger Suite 2018-2 (Schrödinger, LLC, New York, NY, USA).
3.4. Thermostability of Lysosomal Acid α-Glucosidase (GAA)
The enzyme GAA was incubated at 47 ◦C in 100 mM McIlvaine buffer (pH 6.8) containing 0.25%
sodium taurocholate and 0.1% Triton X-100 for 0, 20, 40, and 60 min. After incubation, the remaining
GAA activity was assayed immediately using 4 mM 4-methylumbelliferyl-α-d-glucopyranoside
as substrate.
4. Conclusions
Iminosugars competitively inhibit glycosidases due to homology with the corresponding
substrate. Therefore, piperidine iminosugars that faithfully mimic the stereochemistry of the terminal
hexopyranose cleaved by exo-glucosidase are expected to show strong inhibition. However, it is
difficult to define subtle differences in the isoenzyme that are localized in multiple organs and
tissues. The present work elucidated the following features: (a) GAA and ER α-glucosidase II have
a high degree of structural and sequence similarity at the glucose-recognition site; (b) LAB had the
same level of inhibitory activity (IC50 = 0.52 µM) as DNJ (IC50 = 0.15 µM), and does not change
recognition by GAA; (c) in contrast, the selectivity index (ER α-Glc II/GAA) of LAB was lower than
DNJ, thus, the selectivity toward GAA cannot be obtained simply by changing the ring structure;
(d) α-1-C-heptyl-LAB showed the most potent inhibition of GAA, with an IC50 value of 0.44 µM,
furthermore, it displayed a remarkable selectivity (SI value of 168.2), which is 31-fold better than the
parent LAB; (e) the MD simulation suggested that the ligand-binding conformation stability gradually
improved with the increasing length of the alkyl chain, and a much longer alkyl chain than butyl is
required for achieving this; (f) docking calculations suggested that the binding conformations and
orientations of α-1-C-heptyl-LAB and monosaccharide mimics (DNJ and LAB) in GAA are clearly
different—It had the lower number of hydrogen bonds, but it formed the characteristic hydrophobic
interactions; (g) the amino acid residues surrounding the α-1-C-hexyl-chain storage part in each active
site was clearly different—the space of ER α-glucosidase II was narrower than GAA, and it cannot
accommodate the extension of alkyl chains; (h) α-1-C-heptyl-LAB improved the thermostability of
GAA in vitro at the same level as LAB.
Thus, our findings suggested that focusing on the alkyl chain storage site could improve the
selectivity toward GAA and the ligand-binding conformation stability.
Supplementary Materials: The following are available online, Figure S1: Interactions of deoxynojirimycin with
GAA and ER α-glucosidase. Figure S2: Water molecules found in the ligand-binding site. The water molecules
surrounded by dashed circles were used for the docking analyses.
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